We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · June 13, 2022

Tiragolumab Plus Atezolizumab vs Placebo Plus Atezolizumab as a First-Line Treatment for PD-L1–Selected NSCLC

The Lancet Oncology


Additional Info

The Lancet Oncology
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
Lancet Oncol 2022 May 13;[EPub Ahead of Print], BC Cho, DR Abreu, M Hussein, M Cobo, AJ Patel, N Secen, KH Lee, B Massuti, S Hiret, JCH Yang, F Barlesi, DH Lee, LP Ares, RW Hsieh, NS Patil, P Twomey, X Yang, R Meng, ML Johnson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading